Visible results with DUPIXENT

Actual patients in a Phase 3 pediatric DUPIXENT trial (AD-1652). All patients were prescribed concomitant TCS based on the clinical trial program. Patients 1, 2, and 3 were considered clinical responders. Individual results may vary.

In DUPIXENT clinical trials including children, the primary endpoint was the proportion of subjects with an Investigator’s Global Assessment (IGA) of 0 (clear) or 1 (almost clear) at Week 16.1

Patient 1: 6-year-old achieved a 3-point improvement in IGA2

DRAG TO SEE
RESULTS

Patient 2: 10-year-old achieved a 3-point improvement in IGA2

DRAG TO SEE
RESULTS

Patient 3: 9-year-old achieved a 3-point improvement in IGA2

DRAG TO SEE
RESULTS

Patient 4: 6-year-old achieved a 1-point improvement in IGA2

DRAG TO SEE
RESULTS

A clinical responder was defined as a patient achieving IGA 0 or 11

  • Patient 4 did not meet the primary endpoint in the clinical trial based on their IGA score at Week 16

Clearer skin demonstrated in children IN AD-1652

6-11 years
Skin clearance at Week 16
(primary endpoint)1-3,a,b

aFull Analysis Set includes all subjects randomized.1

bIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.1

cAt Day 1, subjects (baseline weight <30 kg) received 600 mg of DUPIXENT.1

dAt Day 1, subjects (baseline weight ≥30 kg) received 400 mg of DUPIXENT.1

EXPLORE MORE IGA
EFFICACY RESULTS

View adult data VIEW ADOLESCENT
(12 TO 17 YEARS) DATA VIEW INFANT TO PRESCHOOLER
(6 MONTHS TO 5 YEARS) DATA

IGA assesses the overall severity of the clinical signs of atopic dermatitis2

A 0- to 4-point scoring system of the overall severity of atopic dermatitis skin lesions2

 
4

Severe
Disease

Severe erythema and severe
papulation/infiltration

3

Moderate
Disease

Moderate erythema and moderate
papulation/infiltration

2

Mild
Disease

Mild erythema and mild
papulation/infiltration

1

Almost
Clear

Just perceptible erythema, and
just perceptible papulation/infiltration

0

Clear
 

No inflammatory signs of atopic dermatitis  

A clinical responder
was defined as a
patient achieving IGA 0
or 1 and at least a
2-point improvement
from baseline1

IGA, Investigator’s Global Assessment.
Example representation of IGA scoring. Not an actual patient.

Dosage and administration

Thinking about prescribing DUPIXENT?
Find the information you need to get started.

Explore ADMINISTRATION Options